{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:22:11Z","timestamp":1794118931339,"version":"4.8.0"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Heart failure with preserved ejection fraction (HFpEF), defined by an ejection fraction &amp;gt;50%, has emerged as the most prevalent form of heart failure at the community level. Multiple comorbidities, including diabetes, hypertension, obesity, atrial fibrillation, renal diseases, and autoimmune conditions, have been linked to its development. These conditions share common pathways involving oxidative stress, metabolic dysregulation, ischemia, and a chronic inflammatory milieu.<\/jats:p><\/jats:sec><jats:sec><jats:title>Observations<\/jats:title><jats:p>Patients with autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc) exhibit an increased risk of developing HFpEF, often through mechanisms involving chronic inflammation and endothelial dysfunction, which precede the clinical manifestation of HFpEF. Clinical studies have demonstrated that the risk of developing HFpEF exists independently of traditional cardiovascular risk factors, underscoring the pivotal role of chronic inflammation and autoimmunity as key contributors to its pathogenesis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and relevance<\/jats:title><jats:p>The translational implication is that the distinct inflammatory pathways driving these autoimmune diseases (e.g., myeloid-T cells and T-B cell-mediated inflammation in RA, and B cell-driven inflammation in SLE and SSc) should become personalized therapeutic targets to prevent HFpEF progression. Early intervention with novel therapies, such as sodium-glucose cotransporter type 2 (SGLT2) inhibitors, could be crucial in managing these patients during the early disease stages. Additionally, the H2FPEF score should be routinely employed to facilitate early diagnosis and risk stratification, providing a robust framework for personalized management strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1557312","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T05:42:40Z","timestamp":1760506960000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Autoimmune inflammation as a key risk factor for heart failure with preserved ejection fraction: the different types of inflammation driving to HFpEF"],"prefix":"10.3389","volume":"12","author":[{"given":"Elisa","family":"Gremese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Perniola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Ceolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Ferraccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.hfc.2014.04.003","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"10","author":"Andersson","year":"2014","journal-title":"Heart Fail Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1161\/CIR.0000000000001142","article-title":"Correction to: 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"147","author":"Heidenreich","year":"2023","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1161\/CIRCHEARTFAILURE.107.743146","article-title":"Death in heart failure: a community perspective","volume":"1","author":"Henkel","year":"2008","journal-title":"Circ Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","article-title":"A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010","volume":"175","author":"Gerber","year":"2015","journal-title":"JAMA Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1093\/eurheartj\/ehz158","article-title":"The continuous heart failure spectrum: moving beyond an ejection fraction classification","volume":"40","author":"Triposkiadis","year":"2019","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"131657","DOI":"10.1016\/j.ijcard.2023.131657","article-title":"Myeloperoxidase, carnitine, and derivatives of reactive oxidative metabolites in heart failure with preserved versus reduced ejection fraction: a meta-analysis","volume":"399","author":"Wong","year":"2024","journal-title":"Int J Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/J.amjcard.2021.11.045","article-title":"Inflammatory markers and risk of heart failure with reduced to preserved ejection fraction","volume":"167","author":"Albar","year":"2022","journal-title":"Am J Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s00392-021-01907-x","article-title":"Diastolic dysfunction in individuals with and without heart failure with preserved ejection fraction","volume":"111","author":"Wenzel","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jacbts.2017.07.013","article-title":"Murine models of heart failure with preserved ejection fraction: a \"fishing expedition\"","volume":"2","author":"Valero-Munoz","year":"2017","journal-title":"JACC Basic Transl Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1161\/CIRCRESAHA.111.300096","article-title":"Synchrotron radiation imaging for advancing our understanding of cardiovascular function","volume":"112","author":"Shirai","year":"2013","journal-title":"Circ Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.bpj.2013.01.037","article-title":"Myosin heads are displaced from actin filaments in the in situ beating rat heart in early diabetes","volume":"104","author":"Jenkins","year":"2013","journal-title":"Biophys J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.yjmcc.2019.10.005","article-title":"Diastolic dysfunction is initiated by cardiomyocyte impairment ahead of endothelial dysfunction due to increased oxidative stress and inflammation in an experimental prediabetes model","volume":"137","author":"Waddingham","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"716332","DOI":"10.3389\/fphar.2021.716332","article-title":"Potential role of protein kinase C in the pathophysiology of diabetes-associated atherosclerosis","volume":"12","author":"Lien","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.jacc.2006.06.082","article-title":"Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness","volume":"49","author":"Noma","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1101\/gad.11.4.463","article-title":"Activation of the nuclear factor-kappaB by rho, CDC42, and Rac-1 proteins","volume":"11","author":"Perona","year":"1997","journal-title":"Genes Dev"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e015602","DOI":"10.1161\/JAHA.119.015602","article-title":"Oxidative stress is associated with diastolic dysfunction in women with ischemia with no obstructive coronary artery disease","volume":"9","author":"Raad","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1755-5922.2010.00218.x","article-title":"Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy","volume":"30","author":"Elmarakby","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature21363","article-title":"Inflammation, metaflammation and immunometabolic disorders","volume":"542","author":"Hotamisligil","year":"2017","journal-title":"Nature"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.3390\/jcm9072090","article-title":"Endothelial dysfunction: a contributor to adverse cardiovascular Remodeling and heart failure development in type 2 diabetes beyond accelerated Atherogenesis","volume":"9","author":"Gamrat","year":"2020","journal-title":"J Clin Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.3390\/ijerph20054433","article-title":"The relationship of left ventricular diastolic dysfunction and asymmetrical Dimethylarginine as a biomarker of endothelial dysfunction with cardiovascular risk assessed by systematic coronary risk Evaluation2 algorithm and heart failure-a cross-sectional study","volume":"20","author":"Su\u0161i\u0107","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mayocpiqo.2018.12.006","article-title":"Rethinking endothelial dysfunction as a crucial target in fighting heart failure","volume":"3","author":"Premer","year":"2019","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e011107","DOI":"10.1161\/CIRCHEARTFAILURE.123.011107","article-title":"Empagliflozin improves diastolic function in HFpEF by Restabilizing the mitochondrial respiratory chain","volume":"17","author":"Schauer","year":"2024","journal-title":"Circ Heart Fail"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1084\/jem.20171274","article-title":"Cardiac macrophages promote diastolic dysfunction","volume":"215","author":"Hulsmans","year":"2018","journal-title":"J Exp Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.immuni.2021.07.003","article-title":"Resident cardiac macrophages mediate adaptive myocardial remodeling","volume":"54","author":"Wong","year":"2021","journal-title":"Immunity"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.immuni.2022.08.009","article-title":"Resident cardiac macrophages: heterogeneity and function in health and disease","volume":"55","author":"Zaman","year":"2022","journal-title":"Immunity"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/cr.2010.144","article-title":"Oncostatin M inhibits myoblast differentiation and regulates muscle regeneration","volume":"21","author":"Xiao","year":"2011","journal-title":"Cell Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1161\/CIRCRESAHA.118.314028","article-title":"Tissue resident CCR2- and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury","volume":"124","author":"Bajpai","year":"2019","journal-title":"Circ Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.7326\/0003-4819-137-8-200210150-00006","article-title":"Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The cardiovascular health study","volume":"137","author":"Gottdiener","year":"2002","journal-title":"Ann Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1001\/jama.296.18.2209","article-title":"Systolic and diastolic heart failure in the community","volume":"296","author":"Bursi","year":"2006","journal-title":"JAMA"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","article-title":"Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review","volume":"73","author":"McHugh","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12916-023-02764-3","article-title":"Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions","volume":"21","author":"Fauchier","year":"2023","journal-title":"BMC Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/HCO.0000000000000732","article-title":"Atrial fibrillation in patients with heart failure with preserved ejection fraction","volume":"35","author":"Aldaas","year":"2020","journal-title":"Curr Opin Cardiol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jacc.2005.09.022","article-title":"Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the acute decompensated heart failure national registry (ADHERE) database","volume":"47","author":"Yancy","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/jama.296.18.2217","article-title":"Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure","volume":"296","author":"Gheorghiade","year":"2006","journal-title":"JAMA"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1161\/CIRCULATIONAHA.108.815944","article-title":"Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the national heart, lung, and blood institute","volume":"119","author":"Lee","year":"2009","journal-title":"Circulation"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/eurheartj\/eht066","article-title":"Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND","volume":"34","author":"Brouwers","year":"2013","journal-title":"Eur Heart J"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.jacc.2014.01.087","article-title":"Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment","volume":"64","author":"Damman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1136\/ard.2010.143396","article-title":"The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study","volume":"70","author":"Lindhardsen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/art.41979","article-title":"Myocardial dysfunction and heart failure in rheumatoid arthritis","volume":"74","author":"Park","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"j2099","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1365-2362.2007.01772.x","article-title":"Vascular stiffness in familial hypercholesterolaemia is associated with C-reactive protein and cholesterol burden","volume":"37","author":"Cheng","year":"2007","journal-title":"Eur J Clin Investig"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jama.289.2.194","article-title":"Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic","volume":"289","author":"Redfield","year":"2003","journal-title":"JAMA"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1001\/archinternmed.2011.244","article-title":"Mortality rate in patients with diastolic dysfunction and normal systolic function","volume":"171","author":"Halley","year":"2011","journal-title":"Arch Intern Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jama.2011.1201","article-title":"Progression of left ventricular diastolic dysfunction and risk of heart failure","volume":"306","author":"Kane","year":"2011","journal-title":"JAMA"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1136\/ard.2009.124362","article-title":"Increased prevalence of diastolic dysfunction in rheumatoid arthritis","volume":"69","author":"Liang","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s13075-021-02629-1","article-title":"Accelerated diastolic dysfunction in premenopausal women with rheumatoid arthritis","volume":"23","author":"Kim","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.3899\/jrheum.101136","article-title":"High prevalence of subclinical left ventricular dysfunction in patients with psoriatic arthritis","volume":"38","author":"Shang","year":"2011","journal-title":"J Rheumatol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1136\/ard.2008.095836","article-title":"Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients","volume":"68","author":"Hachulla","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10238-019-00600-8","article-title":"Early echocardiographic detection of left ventricular diastolic dysfunction in patients with systemic lupus erythematosus asymptomatic for cardiovascular disease","volume":"20","author":"Leone","year":"2020","journal-title":"Clin Exp Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"102884","DOI":"10.1016\/j.jaut.2022.102884","article-title":"Left ventricular size and function in patients with systemic lupus erythematosus associate with lupus anticoagulant: an echocardiographic follow-up study","volume":"132","author":"Myhr","year":"2022","journal-title":"J Autoimmun"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mvr.2014.08.003","article-title":"Impaired coronary microvascular and left ventricular diastolic function in patients with inflammatory bowel disease","volume":"97","author":"Caliskan","year":"2015","journal-title":"Microvasc Res"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1177\/0003319720918509","article-title":"Aortic stiffening is an Extraintestinal manifestation of inflammatory bowel disease: review of the literature and expert panel statement","volume":"71","author":"Zanoli","year":"2020","journal-title":"Angiology"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"97","DOI":"10.31083\/j.rcm.2021.01.277","article-title":"Role of coronary microvascular dysfunction in heart failure with preserved ejection fraction","volume":"22","author":"Tona","year":"2021","journal-title":"Rev Cardiovasc Med"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.clpt.2006.05.011","article-title":"Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis","volume":"80","author":"Cardillo","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s10067-007-0803-y","article-title":"TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis","volume":"27","author":"Bosello","year":"2008","journal-title":"Clin Rheumatol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1002\/art.24502","article-title":"Improved endothelial function after endothelin receptor blockade in patients with systemic sclerosis","volume":"60","author":"Cardillo","year":"2009","journal-title":"Arthritis Rheum"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"7320","DOI":"10.1038\/s41598-017-07574-1","article-title":"Endothelial dysfunction in systemic lupus erythematosus \u2013 a case-control study and an updated meta-analysis and meta-regression","volume":"7","author":"Mak","year":"2017","journal-title":"Sci Rep"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2020.01.028","article-title":"Endothelial dysfunction and arterial stiffness in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"297","author":"Mendoza-Pinto","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/03009742.2019.1628297","article-title":"Subclinical atherosclerosis and endothelial dysfunction in patients with polymyalgia rheumatica: a pilot study","volume":"49","author":"Santoro","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/cvr\/cvac095","article-title":"Flow-mediated dilation reference values for evaluation of endothelial function and cardiovascular health","volume":"119","author":"Heiss","year":"2023","journal-title":"Cardiovasc Res"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/cvr\/cvaa085","article-title":"Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on atherosclerosis and vascular biology, aorta and peripheral vascular diseases, coronary pathophysiology and microcirculation, and thrombosis","volume":"117","author":"Alexander","year":"2021","journal-title":"Cardiovasc Res"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/s0167-5273(99)00203-x","article-title":"Endothelial dysfunction associated with left ventricular diastolic dysfunction in patients with coronary heart disease","volume":"72","author":"Ma","year":"2000","journal-title":"Int J Cardiol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/annrheumdis-2012-203028","article-title":"Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus","volume":"73","author":"Parker","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1002\/art.23798","article-title":"The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population","volume":"58","author":"Davis","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/acr.24804","article-title":"Association between inflammation, incident heart failure, and heart failure subtypes in patients with rheumatoid arthritis","volume":"75","author":"Huang","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.jacc.2016.12.033","article-title":"Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure","volume":"69","author":"Mantel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3899\/jrheum.221170","article-title":"Trends in incidence of chronic heart failure in patients with rheumatoid arthritis: a population-based study validating different heart failure definitions","volume":"50","author":"Myasoedova","year":"2023","journal-title":"J Rheumatol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"e014661","DOI":"10.1161\/JAHA.119.014661","article-title":"Heart failure risk associated with rheumatoid arthritis-related chronic inflammation","volume":"9","author":"Ahlers","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.3390\/jcm10143180","article-title":"Antiphospholipid antibodies and heart failure with preserved ejection fraction. The Multicenter ATHERO-APS study","volume":"10","author":"Pastori","year":"2021","journal-title":"J Clin Med"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2019.11.013","article-title":"Differential associations of chronic inflammatory diseases with incident heart failure","volume":"8","author":"Prasada","year":"2020","journal-title":"JACC Heart Fail"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"ehad 655.1140","DOI":"10.1093\/eurheartj\/ehad655.1140","article-title":"Impact of systemic lupus erythematosus on outcomes in patients hospitalized with acute decompensated heart failure with reduced and preserved ejection fraction: a national inpatient sample study","volume":"44","author":"Nomigolzar","year":"2016","journal-title":"Eur Heart J"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2217\/fca-2020-0238","article-title":"Prevalence and prognostic significance of heart failure with preserved ejection fraction in systemic sclerosis","volume":"18","author":"Fontes Oliveira","year":"2022","journal-title":"Futur Cardiol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"e008478","DOI":"10.1161\/CIRCHEARTFAILURE.121.008478","article-title":"Long-term trajectories of left ventricular ejection fraction in patients with chronic inflammatory diseases and heart failure: an analysis of electronic health records","volume":"14","author":"Rivera","year":"2021","journal-title":"Circ Heart Fail"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.jchf.2024.04.016","article-title":"Autoimmune disorders in heart failure with preserved ejection fraction","volume":"12","author":"Tada","year":"2024","journal-title":"JACC Heart Fail"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","article-title":"The pathogenesis of rheumatoid arthritis","volume":"55","author":"Alivernini","year":"2022","journal-title":"Immunity"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2013 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1056\/NEJMe2400203","article-title":"CAR T cells \u2013 a new horizon for autoimmunity?","volume":"390","author":"Isaacs","year":"2024","journal-title":"N Engl J Med"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"102873","DOI":"10.1016\/j.jaut.2022.102873","article-title":"B cell-targeted therapies in systemic lupus erythematosus","volume":"132","author":"Arbitman","year":"2022","journal-title":"J Autoimmun"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.autrev.2011.04.013","article-title":"B cells in systemic sclerosis: a possible target for therapy","volume":"10","author":"Bosello","year":"2011","journal-title":"Autoimmun Rev"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"104013","DOI":"10.1016\/j.ebiom.2022.104013","article-title":"Interleukin-6 inhibition in ST-elevation myocardial infarction: immune cell profile in the randomised ASSAIL-MI trial","volume":"80","author":"Huse","year":"2022","journal-title":"EBioMedicine"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/CIRCRESAHA.119.316530","article-title":"T cell Costimulation blockade blunts age-related heart failure","volume":"127","author":"Martini","year":"2020","journal-title":"Circ Res"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"ytz131","DOI":"10.1093\/ehjcr\/ytz131","article-title":"Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: a case series","volume":"3","author":"Tsch\u00f6pe","year":"2019","journal-title":"Eur Heart J Case Rep"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"175126","DOI":"10.1016\/j.ejphar.2022.175126","article-title":"Colchicine alleviates inflammation and improves diastolic dysfunction in heart failure rats with preserved ejection fraction","volume":"929","author":"Shen","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.acvdsp.2022.10.097","article-title":"Effects of COLchicine on inflammation, myocardial damage and microvascular dysfunction in heart failure with preserved ejection fraction \u2013 the COLpEF trial","volume":"15","author":"Bourcier","year":"2023","journal-title":"Arch Cardiovasc Dis Suppl"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"EMPEROR-preserved trial investigators. Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"e018549","DOI":"10.1161\/JAHA.120.018549","article-title":"Interleukin 6 and development of heart failure with preserved ejection fraction in the general population","volume":"10","author":"Chia","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"e010051","DOI":"10.1161\/CIRCHEARTFAILURE.122.010051","article-title":"Adverse outcomes associated with Interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction","volume":"16","author":"Mooney","year":"2023","journal-title":"Circ Heart Fail"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.3899\/jrheum.131540","article-title":"Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging","volume":"41","author":"Kobayashi","year":"2014","journal-title":"J Rheumatol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"e005036","DOI":"10.1161\/CIRCHEARTFAILURE.118.005036","article-title":"IL-1 blockade in patients with heart failure with preserved ejection fraction","volume":"11","author":"Van Tassell","year":"2018","journal-title":"Circ Heart Fail"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1\u03b2 inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2020","journal-title":"Eur Heart J"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"e006570","DOI":"10.1161\/CIRCHEARTFAILURE.119.006570","article-title":"Inflammation and circulating natriuretic peptide levels","volume":"13","author":"Fish-Trotter","year":"2020","journal-title":"Circ Heart Fail"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-023-01620-3","article-title":"The IL-17 family in diseases: from bench to bedside","volume":"8","author":"Huangfu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cjca.2019.06.021","article-title":"Effects of interleukin 17A inhibition on myocardial deformation and vascular function in psoriasis","volume":"36","author":"Makavos","year":"2020","journal-title":"Can J Cardiol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.yjmcc.2018.08.005","article-title":"Interleukin-17 enhances cardiac ventricular remodeling via activating MAPK pathway in ischemic heart failure","volume":"122","author":"Chang","year":"2018","journal-title":"J Mol Cell Cardiol"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.hlc.2020.06.017","article-title":"Use of inflammatory biomarkers and real-time cardiac catheterisation to evaluate the left ventricular diastolic function in patients with diastolic heart failure","volume":"30","author":"Xu","year":"2021","journal-title":"Heart Lung Circ"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.rec.2016.11.005","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"69","author":"Ponikowski","year":"2016","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"11548","DOI":"10.1038\/s41598-022-15436-8","article-title":"Effects of immune-mediated inflammatory diseases on cardiovascular diseases in patients with type 2 diabetes: a nationwide population-based study","volume":"12","author":"Kwon","year":"2022","journal-title":"Sci Rep"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3899\/jrheum.180732","article-title":"Statins and mortality in connective tissue diseases: should we resume the cardio-rheumatology spirit in our clinics?","volume":"45","author":"Gremese","year":"2018","journal-title":"J Rheumatol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2023.2020","article-title":"Heart failure with preserved ejection fraction: a review","volume":"329","author":"Redfield","year":"2023","journal-title":"JAMA"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1557312\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T05:42:42Z","timestamp":1760506962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1557312\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":106,"alternative-id":["10.3389\/fmed.2025.1557312"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1557312","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"1557312"}}